Chiang K Y, Weisdorf D J, Davies S M, Enright H, Kersey J H, McGlave P B, Miller W, Ramsay N K, Steinbuch M, Wagner J E, Blazar B R
Department of Pediatrics and Medicine, University of Minnesota, Minneapolis 55455, USA.
Bone Marrow Transplant. 1996 Jan;17(1):39-42.
Twenty-three second bone marrow transplants (BMT) were performed between October 1987 and January 1994 for patients with malignant relapse following initial BMT. For first BMT, twenty-one of 23 (91%) were conditioned with cyclophosphamide plus total body irradiation. For second BMT, a uniform conditioning regimen consisting of busulfan and cyclophosphamide was used. Eleven patients had chronic myelogenous leukemia, seven acute leukemia, four lymphoma, and one myelodysplastic syndrome. Median patient age at second BMT was 32 years, the median time between first BMT and relapse was 22 months, and the median time to second BMT after relapse was 5 months. The second BMT marrow source included: autologous marrow (1), unrelated donors (4), new matched sibling donors (5) and same matched sibling donors as the first BMT (13). The Kaplan-Meier disease-free survival and survival rates at 3 years were 38 and 43%, respectively (median follow-up of survivors was 45 and 48 months, respectively), and five patients survive disease-free at 4-6 years. Nine of the 13 deaths occurred within 100 days after second BMT; eight had relapsed within 1 year of the first BMT. We conclude that: (1) second BMT can offer durable long-term survival in certain patients, especially those who relapse late after first transplant; (2) busulfan and cyclophosphamide is a suitable conditioning regimen for second BMT.
1987年10月至1994年1月期间,对初次骨髓移植(BMT)后恶性复发的患者进行了23例二次骨髓移植。初次BMT时,23例中有21例(91%)采用环磷酰胺加全身照射进行预处理。二次BMT时,采用白消安和环磷酰胺组成的统一预处理方案。11例患者患有慢性粒细胞白血病,7例患有急性白血病,4例患有淋巴瘤,1例患有骨髓增生异常综合征。二次BMT时患者的中位年龄为32岁,初次BMT与复发之间的中位时间为22个月,复发后至二次BMT的中位时间为5个月。二次BMT的骨髓来源包括:自体骨髓(1例)、无关供者(4例)、新的匹配同胞供者(5例)和与初次BMT相同的匹配同胞供者(13例)。3年时的无病生存率和总生存率分别为38%和43%(幸存者的中位随访时间分别为45个月和48个月),5例患者在4至6年时无病存活。13例死亡患者中有9例在二次BMT后100天内死亡;8例在初次BMT后1年内复发。我们得出以下结论:(1)二次BMT可以使某些患者获得持久的长期生存,尤其是那些初次移植后复发较晚的患者;(2)白消安和环磷酰胺是二次BMT合适的预处理方案。